Clinical Trial Update: Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec [Phase 2]

View source ↗

Summary

Open-label Phase II study of sorafenib (BAY 43-9006) in chronic myelogenous leukemia patients resistant to imatinib (Gleevec) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED